ESC-HFA 2024: Late-Breaking Science Video Collection
Published: 14 May 2024
-
Views:
1204
-
Likes:
7
-
Views:
1204
-
Likes:
7
-
Up Next -
8m 37sPart 1 | Session 4 Late-Breaker Discussion: Findings from PACT-HF
-
2m 45sPart 2 | Session 1 Remote Patient Monitoring for Patients With Heart Failure: TELESAT -
5m 3sPart 2 | Session 2 Cordella PA Sensor System in NYHA Class III HF Patients: PROACTIVE-HF -
7m 19s -
5m 24sPart 2 | Session 4 Timing of Cardio-Kidney Protection with SGLT2i -
2m 54s -
4m 46s -
4m 40sPart 2 | Session 7 FINE-HEART: Design & Baseline Characteristics -
11m 58sPart 2 | Session 8 HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
-
15m 26sPart 1 | Session 1 HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie Harriette Van Spall, Mark Petrie
-
10m 15sPart 1 | Session 2 Late-Breaker Discussion: The TITRATE-HF Study Harriette Van Spall, Jasper J Brugts
Overview
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024.
Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests.
For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators.
More from this programme
Part 1
Late-breaker Discussions with Dr Van Spall
Part 2
Expert Interviews
About the episode
HFA 2024 — Late-breaker host, Dr Harriette Van Spall sat down with Dr Mikhail Kosiborod to discuss insights from the STEP-HFpEF programme.
STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. This discussion centers around the background of the primary results of STEP-HFpEF, specifically in terms of the patients' NTproBNP levels. This study analysed both the effect of semaglutide on NTproBNP, as well as the effect of semaglutide on the primary and secondary endpoints of STEP-HFpEF according to patients' baseline NTproBNP.
Findings showed that all patients regardless of NTproBNP benefited from semaglutide as compared to placebo, both in terms of improvement in KCCQ Clinical Summary Score, and weight loss. However, patients at higher NTproBNP levels had greater improvement in KCCQ score than those with lower NTproBNP.
Recorded onsite at HFA 24, Lisbon.
Support: This is an independent discussion produced by Radcliffe Cardiology.
Editor: Mirjam Boros, Jordan Rance
Video Specialist: Tom Green, Oliver Miles
Interviewer: Jonathan McKenna
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Mikhail Kosiborod
Cardiologist
Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.
He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.
Comments